Earlier quoted context omitted.
> I wrote a post about why GATK - one of the most popular bioinformatic tools in Next Generation Sequencing should not be put into a clinical pipeline: I've seen you link to your blog post a couple of times now, and I still think it's misleading. I do wonder whether your conflict of interest (selling competing software) has led you to come to a pretty unreasonable conclusion. (My conflict of interest is that I have a…
On your first point, my post detailed that 23andMe confirmed it was a GATK bug that introduced the bogus variants and the bug was fixed in the next minor release of the software. There are comments on the post from members of 23andMe and the GATK team that go into more details as well. On your second point. 23andMe had every incentive to pay attention to their output, but it is fair to say it's their responsibility f…
Sure, I agree with that. And I would agree if you would say "Using bleeding-edge nightly builds of %s for production-level clinical work is a bad idea," whether %s was the GATK or the Linux kernel. I would be in such complete agreement that I wouldn't even feel compelled to respond to your posts if that's what you would say originally, rather than saying, "the GATK ... should not be put into a clinical pipeline". The former is accepted practice industry-wide; the latter reads like FUD and cannot be justified by one anecdote.
> You know though, the conflict of interest dismissal is something I run into more than I would expect.
Regarding conflict of interest, my point in trying to understand your potential interests, and also disclosing my own so that you can see where I'm coming from. That's not a dismissal, it's a search for a more complete picture. Interested parties are often the most qualified commenters, anyway, but their conclusions merit review.
Hopefully people wouldn't dismiss my views because of my Broad connection, anymore than they would dismiss yours if you sold a competing product.